JP2013508282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508282A5 JP2013508282A5 JP2012534324A JP2012534324A JP2013508282A5 JP 2013508282 A5 JP2013508282 A5 JP 2013508282A5 JP 2012534324 A JP2012534324 A JP 2012534324A JP 2012534324 A JP2012534324 A JP 2012534324A JP 2013508282 A5 JP2013508282 A5 JP 2013508282A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antiviral agent
- receptor agonist
- hydroxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003443 antiviral agent Substances 0.000 claims 16
- 101150109738 Ptger4 gene Proteins 0.000 claims 13
- 239000000018 receptor agonist Substances 0.000 claims 13
- 229940044601 receptor agonist Drugs 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000003612 virological effect Effects 0.000 claims 4
- OJIGXQJDLFUVFM-MBLRWRSDSA-N (5e)-5-[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxy-4-methyloct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]-5-cyanopentanoic acid Chemical group O1\C(=C(/CCCC(O)=O)C#N)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CCCC)[C@H](O)C[C@@H]21 OJIGXQJDLFUVFM-MBLRWRSDSA-N 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 229960002890 beraprost Drugs 0.000 claims 2
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical group [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960003752 oseltamivir Drugs 0.000 claims 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- OJIGXQJDLFUVFM-AGCJUELTSA-N (5e)-5-[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s,4s)-3-hydroxy-4-methyloct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]-5-cyanopentanoic acid Chemical compound O1\C(=C(/CCCC(O)=O)C#N)C[C@@H]2[C@@H](/C=C/[C@@H](O)[C@@H](C)CCCC)[C@H](O)C[C@@H]21 OJIGXQJDLFUVFM-AGCJUELTSA-N 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- XBYGDAGWXPBGNY-UHFFFAOYSA-N 4-(1-benzofuran-5-yl)butanoic acid Chemical compound OC(=O)CCCC1=CC=C2OC=CC2=C1 XBYGDAGWXPBGNY-UHFFFAOYSA-N 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical group C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical group NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 1
- 229940126181 ion channel inhibitor Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950004935 nileprost Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 1
- 229960001084 peramivir Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002911 sialidase inhibitor Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25156109P | 2009-10-14 | 2009-10-14 | |
| US61/251,561 | 2009-10-14 | ||
| PCT/US2010/052506 WO2011047048A1 (en) | 2009-10-14 | 2010-10-13 | Combination therapy treatment for viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508282A JP2013508282A (ja) | 2013-03-07 |
| JP2013508282A5 true JP2013508282A5 (enExample) | 2013-12-05 |
Family
ID=43063744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534324A Pending JP2013508282A (ja) | 2009-10-14 | 2010-10-13 | ウイルス感染のための併用療法処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120190637A1 (enExample) |
| EP (1) | EP2488168A1 (enExample) |
| JP (1) | JP2013508282A (enExample) |
| KR (1) | KR20120093955A (enExample) |
| CN (1) | CN102655859A (enExample) |
| BR (1) | BR112012008959A2 (enExample) |
| CA (1) | CA2777384A1 (enExample) |
| NZ (1) | NZ599128A (enExample) |
| WO (1) | WO2011047048A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2669763C (en) | 2006-11-16 | 2015-02-17 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| CN105555276A (zh) * | 2013-03-15 | 2016-05-04 | 格穆斯药业股份有限公司 | 作为治疗病毒性感染的药剂的贝前列素异构体 |
| WO2015109112A1 (en) * | 2014-01-16 | 2015-07-23 | Gemmus Pharma Inc. | Combination treatment of antibiotic and gpcr agonist for viral/bacterial co-infections |
| EP3609502A1 (en) * | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
| CN111265528A (zh) | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 法匹拉韦在治疗冠状病毒感染方面的应用 |
| WO2021163400A1 (en) | 2020-02-12 | 2021-08-19 | Cytoagents, Inc. | Compositions and methods for treating coronavirus infections |
| CN111184707B (zh) * | 2020-02-20 | 2021-04-27 | 中山大学 | 托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用 |
| KR20230035522A (ko) * | 2020-04-30 | 2023-03-14 | 미노릭스 테라퓨틱스 에스.엘. | 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존 |
| WO2021221111A1 (ja) * | 2020-04-30 | 2021-11-04 | 国立大学法人京都大学 | Rnaウイルス関連疾患の予防又は治療剤 |
| US20210386725A1 (en) * | 2020-06-11 | 2021-12-16 | Chang Gung University | Method for inhibiting coronavirus infection and replication |
| US20240009214A1 (en) | 2020-12-02 | 2024-01-11 | Cipla Limited | Method of Treating Viral Infection |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2845770A1 (de) | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| DE3048906A1 (de) | 1980-12-19 | 1982-07-15 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体 |
| DE3226550A1 (de) | 1982-07-13 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3306123A1 (de) | 1983-02-18 | 1984-09-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3740838A1 (de) | 1987-11-27 | 1989-06-08 | Schering Ag | Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel |
| EP1339678B1 (en) | 2000-11-27 | 2007-09-26 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| US20030027853A1 (en) | 2001-06-14 | 2003-02-06 | Allergan Sales, Inc. | 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| BR0211364A (pt) | 2001-07-23 | 2004-07-13 | Ono Pharmaceutical Co | Composição farmacêutica para tratamento de doenças associadas com redução na massa óssea compreendendo o agonista ep4 como componente ativo |
| CA2466751A1 (en) | 2001-12-03 | 2003-06-12 | Merck And Co., Inc. | Ep4 receptor agonist, compositions and methods thereof |
| EP1461026A2 (en) | 2001-12-03 | 2004-09-29 | Merck & Co., Inc. | Method for treating ocular hypertension |
| MXPA04009243A (es) | 2002-04-12 | 2005-06-08 | Pfizer | Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6. |
| CA2487977A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
| JP4766875B2 (ja) | 2002-06-06 | 2011-09-07 | メルク フロスト カナダ リミテツド | Ep4受容体作動薬、組成物及びその方法 |
| AU2003258433A1 (en) | 2002-08-28 | 2004-03-19 | Merck Frosst Canada Ltd | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
| WO2004037786A2 (en) | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| WO2004065365A1 (ja) | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | 8−アザプロスタグランジン誘導体およびその医薬用途 |
| KR101077461B1 (ko) | 2003-02-11 | 2011-10-26 | 알러간, 인코포레이티드 | 안압 강하제로서의 10,10-디알킬 프로스탄산 유도체 |
| GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US7326716B2 (en) | 2003-06-06 | 2008-02-05 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| US7015243B2 (en) | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| WO2005027931A1 (en) | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| CA2549935A1 (en) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| WO2005116010A1 (en) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
| US20080234337A1 (en) | 2004-08-10 | 2008-09-25 | Ono Pharmaceutical Co., Ltd. | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist |
| US20080132543A1 (en) | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
| US7994195B2 (en) | 2004-11-04 | 2011-08-09 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
| US7101906B2 (en) | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| JP5014978B2 (ja) | 2005-01-27 | 2012-08-29 | 旭化成ファーマ株式会社 | ヘテロ6員環化合物及びその用途 |
| WO2006137472A1 (ja) | 2005-06-24 | 2006-12-28 | Taisho Pharmaceutical Co., Ltd. | プロスタグランジン誘導体 |
| CA2616608A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
| AU2006275270A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd | EP4 receptor agonist, compositions and methods thereof |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| GB0602900D0 (en) | 2006-02-13 | 2006-03-22 | Glaxo Group Ltd | Novel Compounds |
| WO2007139150A1 (ja) * | 2006-05-30 | 2007-12-06 | The University Of Tokushima | TNFα阻害物質を含有してなる抗インフルエンザウイルス剤 |
| WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| GB0615111D0 (en) | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel compounds |
| GB0615105D0 (en) | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel compounds |
| CN101541778B (zh) | 2006-08-11 | 2014-10-08 | 默克加拿大有限公司 | 作为ep4受体配体的噻吩甲酰胺衍生物 |
| GB0620619D0 (en) | 2006-10-17 | 2006-11-29 | Glaxo Group Ltd | Novel compounds |
| CA2669763C (en) * | 2006-11-16 | 2015-02-17 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| GB0623203D0 (en) | 2006-11-21 | 2007-01-03 | Glaxo Group Ltd | Novel compounds |
| CA2672631A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
| EP1975163A1 (en) * | 2007-03-28 | 2008-10-01 | Bayer Schering Pharma Aktiengesellschaft | Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of influenza a viral infection |
| US7776896B2 (en) | 2007-03-28 | 2010-08-17 | Bayer Schering Pharma Aktiengesellschaft | 5-cyano-prostacyclin derivatives as agents for the treatment of influenza a viral infection |
| EP2147672A4 (en) | 2007-05-08 | 2011-11-02 | Nat University Corp Hamamatsu University School Of Medicine | CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST |
-
2010
- 2010-10-13 JP JP2012534324A patent/JP2013508282A/ja active Pending
- 2010-10-13 EP EP10768160A patent/EP2488168A1/en not_active Withdrawn
- 2010-10-13 US US13/129,108 patent/US20120190637A1/en not_active Abandoned
- 2010-10-13 CA CA2777384A patent/CA2777384A1/en not_active Abandoned
- 2010-10-13 BR BR112012008959A patent/BR112012008959A2/pt not_active IP Right Cessation
- 2010-10-13 CN CN2010800567360A patent/CN102655859A/zh active Pending
- 2010-10-13 NZ NZ599128A patent/NZ599128A/en not_active IP Right Cessation
- 2010-10-13 WO PCT/US2010/052506 patent/WO2011047048A1/en not_active Ceased
- 2010-10-13 KR KR1020127012323A patent/KR20120093955A/ko not_active Ceased
-
2014
- 2014-12-10 US US14/566,354 patent/US20150196578A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508282A5 (enExample) | ||
| US11660307B2 (en) | Methods for treating SARS CoV-2 infections | |
| JP2013518107A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2018030855A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2013508282A (ja) | ウイルス感染のための併用療法処置 | |
| JP2012505836A5 (enExample) | ||
| US20230248712A1 (en) | Methods and compositions for treating rna viral infections | |
| EP4181928A1 (en) | Compositions and methods for treating lung inflammation | |
| JP2008540507A5 (enExample) | ||
| JP2018531273A5 (enExample) | ||
| CA3188776A1 (en) | Method of treating coronavirus infections with cannabinoids and derivatives | |
| JP2010514834A5 (enExample) | ||
| JP2013523740A5 (enExample) | ||
| US20230158103A1 (en) | Pld for use in combination in the treatment of coronavirus | |
| JP2014509637A5 (enExample) | ||
| RU2011105463A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| JP2015500831A5 (enExample) | ||
| JP2014506577A5 (enExample) | ||
| JP2017514829A5 (enExample) | ||
| US20240082228A1 (en) | Sars-cov-2 therapeutics | |
| WO2023102381A1 (en) | Use of pipendoxifene to treat sars-cov-2 infection | |
| JP2015524460A5 (enExample) | ||
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease |